This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Second View: Discussing recent approval for first biologic treatment of COPD with Dupixent.
Ticker(s): REGNWho's the expert?
Dr. Michael Burk
- Board certified pulmonary and critical care physician in a hospital, ICU, and pulmonary clinic setting
- Clinical expertise includes point of care ultrasound evaluation (POCUS), a wide variety of pulmonary diseases including COPD, interstitial lung disease, post-COVID lung disease, asthma, lung cancer, and other respiratory conditions.
- Trained in advanced bronchoscopy procedures including endobronchial ultrasound (EBUS) guided biopsy and robotic bronchoscopy.
Interview GoalThis conversation will focus on the treatment of COPD and the recent approval of the use of Dupixent for patients with COPD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
